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Abstract
We have previously demonstrated that the globular head of the hemagglutinin (HA) antigen fused to flagellin of Salmonella
typhimurium fljB (STF2, a TLR5 ligand) elicits protective immunity to H1N1 and H5N1 lethal influenza infections in mice
(Song et al., 2008, PLoS ONE 3, e2257; Song et al., 2009, Vaccine 27, 5875–5888). These fusion proteins can be efficiently and
economically manufactured in E. coli fermentation systems as next generation pandemic and seasonal influenza vaccines.
Here we report immunogenicity and efficacy results of three vaccine candidates in which the HA globular head of A/
California/07/2009 (H1N1) was fused to STF2 at the C-terminus (STF2.HA1), in replace of domain 3 (STF2R3.HA1), or in both
positions (STF2R3.2xHA1). For all three vaccines, two subcutaneous immunizations of BALB/c mice with doses of either 0.3
or 3 mg elicit robust neutralizing (HAI) antibodies, that lead to .=2 Log10 unit reduction in day 4 lung virus titer and full
protection against a lethal A/California/04/2009 challenge. Vaccination with doses as low as 0.03 mg results in partial to full
protection. Each candidate, particularly the STF2R3.HA1 and STF2R3.2xHA1 candidates, elicits robust neutralizing antibody
responses that last for at least 8 months. The STF2R3.HA1 candidate, which was intermediately protective in the challenge
models, is more immunogenic than the H1N1 components of two commercially available trivalent inactivated influenza
vaccines (TIVs) in mice. Taken together, the results demonstrate that all three vaccine candidates are highly immunogenic
and efficacious in mice, and that the STF2R3.2xHA1 format is the most effective candidate vaccine format.
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Introduction
Vaccination is a primary countermeasure to combat seasonal
and pandemic influenza. Influenza vaccines have been manufac-
tured as live attenuated, inactivated whole virus or split vaccines
produced in embryonated hens’ eggs using a method that was
established over 60 years ago. Recently, mammalian cells have
also been used to manufacture influenza vaccines in Europe. The
major immunogens in these vaccines are viral hemagglutinin (HA)
and neuraminidase (NA) proteins. While these vaccines are
effective, they are inefficient to produce in terms of time and
manufacturing capacity. When a pandemic influenza emerges for
instance, it takes approximately 4–6 months from virus identifi-
cation to production of the first vaccine doses. The collective
experience with vaccine production for the last three influenza
pandemics, particularly the 2009 H1N1 pandemic, has demon-
strated that this timing is insufficient to meet global needs.
Although dose sparing and increased longevity of immunity have
recently been demonstrated when these vaccines are formulated
with adjuvants (AS03 or MF59) [1,2], a next generation
technology for rapid production of pandemic influenza vaccines
is still urgently needed [3,4].
Recombinant technologies alleviate many of the production and
capacity constraints associated with current technologies and
provide a solution to global seasonal and pandemic influenza
vaccine needs. These vaccine platforms include production of
either recombinant HA [5] or virus-like particles consisting of HA,
NA and matrix (M1) proteins [6,7], vaccinia virus based
expression of HA and NA [8], E. coli based expression of
flagellin-HA globular head fusion proteins [9], the HA1 fragment
of HA [10], or the HA2 stalk of HA [11], as well as DNA vector-
based expression of multiple antigens [12].
VaxInnate’s vaccine platform effectively links innate and
adaptive immunity by genetically fusing the immunogen to
flagellin of Salmonella typhimurium (fljB) (STF2). This flagellin fusion
vaccine technology allows rapid development of vaccine seed
clones in a couple of weeks, followed by economical manufactur-
ing of the fusion protein-based vaccines using a well-established E.
coli fermentation system and a standardized purification process.
Flagellin is a TLR5 ligand consisting of domains 0, 1, 2, and 3,
where domain 1 contains the TLR5-binding site [13]. We have
demonstrated that the majority of conformational epitopes of the
HA globular head of an H1N1 virus can be faithfully restored in a
refolded fusion protein [14]. Simultaneous antigen delivery and
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to result in enhanced antigen presentation and induction of
humoral and cell-mediated immune responses.
We have developed a panel of influenza vaccine formats which
differ in the position of attachment of the HA globular heads fused
to flagellin at different positions. Our initial vaccine formats fused
the HA globular head of H1N1 subtypes to the carboxyl-terminus
of flagellin. These seasonal vaccine candidates were highly
immunogenic and protected mice against a lethal H1N1 influenza
infection in mice [14]. The C-terminal format of the A/Solomon
Islands/03/2006 HA globular head vaccine has also been shown
to be well-tolerated and immunogenic in humans [15]. Subse-
quent development of pandemic H5N1 vaccines led to identifica-
tion of a more efficacious alternative format of the vaccine, in
which the HA globular head replaced the domain 3 of flagellin
(STF2R3.HA5) [9]. Here we report promising preclinical
immunogenicity and efficacy results of three vaccine candidates
in which the HA globular head of A/California/07/2009 (H1N1)
was fused to STF2 at the C-terminus (STF2.HA1), in replace of
domain 3 (STF2R3.HA1), or in both positions (STF2R3.2xHA1).
Results
With the emergence of the 2009 H1N1 pandemic we designed,
produced and tested three different formats of the flagellin-HA
vaccine candidates based on the A/California/07/2009 isolate
(Fig. 1). A goal was to evaluate the timing to vaccine production,
the efficiency of production and the relative immunogenicity and
efficacy of the different vaccine formats in a preclinical model. The
far left panel shows a ribbon diagram of the structure of influenza
HA with the HA1-2 domain (HA1) highlighted in green (Fig. 1A).
STF2R3.HA1 consists of one copy of HA in placement of the D3
domain of STF2 (STF2R3.HA1, Fig. 1B & 1E). STF2.HA1
consists of one copy of HA fused to the C terminus of STF2
(STF2.HA1, Fig. 1C & 1E). STF2R3.2xHA1 consists of one copy
of HA fused to the C terminus of STF2 and the second in
replacement of the D3 domain (STF2R3.HA1.2x, Fig. 1D & 1E).
With regards to timing to vaccine production, we were able to
progress from receipt of the HA gene sequence to purified proteins
within 3 weeks. As shown in SDS-PAGE gel (Fig. 2A), purified
STF2.HA1, STF2R3.HA1, and STF2R3.2xHA1 proteins were
detected as single protein bands with predicted molecular weights
of 77 kDa, 67 kDa, and 92 kDa, respectively (Fig. 2A). The purity
as measured by reverse-phase HPLC and endotoxin level
(measured by LAL test) of all lots used in this study are $95%
and #5 EU/mg. All lots were $98% monomers by size exclusion
chromatography, and had low levels of contaminating host nucleic
acids and proteins. Finally, all three candidates induced significant
dose-dependent IL-8 production in an in vitro TLR5 assay using
HEK293 cells (Table 1).
To compare the antigenicity of the vaccine candidates, we
examined the reactivity of the three fusion proteins with ferret post
infection serum specific to A/California/07/2009 (CDC). All
three candidates showed good specific antibody binding activities.
As expected, the STF2R3.2x HA1 format showed the strongest
reactivity after a full-length HA (HA0 CA04) expressed from
baculovirus/insect cells to the ferret serum due to the presence of
two copies of the globular head (Fig. 2B). The STF2.HA1
candidate displayed the weakest reactivity, and the STF2R3.HA1
format showed intermediate reactivity.
In our initial immunogenicity experiment, groups of 10 BALB/
c mice were immunized s.c. twice at a 3-week interval with
doses of 5, 1 and 0.2 mg of STF2.HA1, STF2R3.HA1, and
STF2R3.2xHA1. Post boost sera were prepared and subjected to
an HAI test. The results in Fig. 3A indicated that all three formats
elicited strong HAI responses. At the 1 mg dose level, STF2.HA1,
STF2R3.HA1, and STF2R3.2xHA1 elicited HAI titers of $40 in
70% (GMT=57), 90% (GMT=149), and 100% (GMT=226) of
mice, respectively. At the sub-microgram (0.2 mg) dose, these
candidates were also very immunogenic; STF2.HA1,
STF2R3.HA1, and STF2R3.2xHA1 elicit a HAI titer of $40 in
60% (GMT=46), 90% (GMT=92), and 90% (GMT=106) of
mice, respectively. Overall, STF2R3.2xHA1 was significantly
more effective than the STF2.HA1 format in eliciting neutralizing
antibodies. In addition, the STF2R3.2x HA1 format is more active
in inducing all subclasses of IgG, particularly IgG2a and IgG3
subclasses compared to the STF2.HA1 format (Fig. 3B).
To compare the immunogenicity of our vaccine with commer-
cial TIVs, we selected the intermediate STF2R3.HA1 candidate,
which can be easily purified at the highest yield among all three
candidates. We immunized mice with Fluvirin (Novartis), Fluzone
(Sanofi-Aventis), or STF2R3.HA1 at different doses. HAI titers in
Fig. 4A demonstrate that STF2R3.HA1 elicits significantly higher
HAI titers than Fluvirin or Fluzone. Specifically, the 1 mg dose of
STF2R3.HA1 elicited a GMT titer of 226; whereas Fluvirin at
9 mg (containing 3 mg of H1 HA) induced a GMT titer of 19. The
H1N1 component of another TIV (Fluzone, Sanofi-Aventis)
displayed equally low immunogenicity, as 2 s.c. immunizations
with Fluzone at 1, 3, and 9 mg (containing 0.3, 1, and 3 mgo fH 1
HA) led to geometric mean HAI titers of 6, 10, and 19,
respectively (Fig. 4A). These results indicate that the
STF2R3.HA1 format candidate vaccine is more immunogenic
than the H1N1 component of two commercial TIVs. Further-
more, mice primed with STF2R3.HA1 and boosted with Fluvirin
generated a significantly higher HAI titer (GMT=121) than those
primed and boosted with Fluvirin (GMT=10) (Fig. 4B).
We next examined the durability of the antibody responses
induced by these vaccine candidates. No neutralizing antibody was
detected in mice following priming with any of these candidates
(Fig. 5). After one booster immunization, all three candidates,
particularly the STF2R3.HA1 and STF2R3.2xHA1, elicited HAI
antibody responses that lasted for at least 8 months after the boost.
These mice, however, did not show a significant anamnestic
antibody response measured as a rise in HAI titers. In contrast,
mice responded to the first STF2.HA1 boost to a lesser extent, but
showed a stronger memory response following the second booster
immunization (Fig. 5).
Two mouse immunogenicity and efficacy experiments were
conducted at Utah State University. Microgram and sub-
microgram doses (prime and boost) of all three vaccine formats
provided full protection against weight loss and death following a
lethal viral (mouse-adapted A/California/04/2009) challenge
(Fig. 6A and Table 2). Similar to earlier results, in these studies
the immunogenicity of the candidates was ranked as
STF2R3.2xHA1.STF2R3.HA1.STF2.HA1 (Table 2). Post viral
challenge, mice (n=10) were monitored for weight change and
survival. Five additional mice from selected groups were
euthanized four days post-infection to determine lung virus titers.
At the discriminating 0.03 mg dose level, the survival rates of the
STF2.HA1, STF2R3.HA1 and STF2R3.2xHA1 groups are 20–
90%, 60–100%, and 90–100%, respectively. In the second efficacy
experiment, mice receiving the STF2.HA1 lost a significantly
higher percentage of weight compared to those receiving the
STF2R3.HA1 and STF2R3.2xHA1 candidates (p,0.001,
0.03 mg/mouse) (Fig. 6A). The survival rates are associated with
1.1, 0.6, and 3.9 log10 unit reduction in lung virus titer for
STF2.HA1, STF2R3.HA1, and STF2R3.2xHA1, respectively
(Fig. 6B). A more dramatic reduction (4.3–4.7 log units) in lung
Flagellin-HA Fusion Vaccines of Pandemic Influenza
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STF2R3.HA1 and STF2R3.2xHA1 candidates. A two log unit
reduction in lung titers was found in mice immunized with
STF2.HA1 (0.3 mg). The weight loss and lung virus titer data
showed a parallel pattern (Fig. 6A & 6B). Therefore, our data
indicate that while all three formats are protective, the relative
effectiveness of the three vaccine formats appears to be in the
order of STF2R3.2xHA1.STF2R3.HA1.STF2.HA1.
Discussion
VaxInnate has developed a flagellin fusion protein-based
vaccine platform that effectively links innate and adaptive
immunity. The flagellin portion of the fusion potentiates the
immune response by triggering TLR5. The HA globular head
contains the majority of HA neutralizing epitopes thereby
eliciting a specific immune response against influenza virus.
Induction of a potent antigen specific immune response
requires the physical linkage of the antigen to flagellin, as co-
delivery of the 2 components failed to induce highly protective
immunity to influenza and flavivirus infections in mice [16,17].
We have previously demonstrated the excellent immunogenicity
and efficacy of this vaccine platform when applied to either
seasonal H1N1 or highly pathogenic avian influenza H5N1 in
animal models [14,9]. More recently we have demonstrated
that a seasonal H1N1 vaccine, VAX125, is well tolerated and
immunogenic in man [15]. Importantly, this vaccine was
extremely well tolerated and highly immunogenic in the
typically poorly responsive elderly population (unpublished
results). Here we report promising preclinical immunogenicity
and efficacy results of three vaccine formats targeting 2009
pandemic H1N1 influenza. The antigenicity profile
(STF2R3.2xHA1.STF2R3.HA1.STF2.HA1) of these three
vaccine candidates is similar to that for previous STF2R3.HA5
and STF2.HA5 (H5N1) VN candidates [9]. These results
confirm previous results and demonstrate that conformational
epitopes of the HA globular head of these candidate vaccines
are well preserved following the purification process.
Figure 1. Ribbon diagram and schematic representation of the flagellin-HA globular head fusion vaccine candidates. HA globular
head and flagellin structures are shown in green and orange, respectively. (A) HA monomer with encircled HA globular head; the HA globular head
(HA1: amino acids 63–285) was genetically fused to the hypervariable region to replace domain 3 of flagellin (STF2R3.HA1, B), the C-terminus
(STF2.HA1, C), or both positions (STF2R3.2xHA1, D). (E) linear schematic representation of recombinant flegallin-HA1 fusion proteins: Indicated are
the flagellin domains D0 (black), D1 (blue), D2 (green), and D3 (red) as well as HA1 (open box) of Influenza A/California/07/2009. Beginning amino
acid numbers of each domain are given.
doi:10.1371/journal.pone.0020928.g001
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izing antibody responses for at least 8 months in mice (Fig. 5).
Following a second booster immunization at month 9, mice
receiving the STF2.HA1 candidate displayed a better anamnestic
antibody response. Higher pre-existing HAI titers in the
STF2R3.HA1- and STF2R3.2xHA1- immunized mice as seen
with TIV vaccinations in humans [18] may have contributed to
the lower fold increases after the third immunization.
Infection with influenza virus or immunization with a live
attenuated influenza vaccine in BALB/c mice elicits predomi-
nantly IgG2a or IgG1 responses [19]. VaxInnate’s flagellin fusion
vaccine candidates elicit all four subclasses of IgG with a Th2-type
response characterized by high levels of IgG1 antibodies in BALB/
c mice. This is expected for a subunit protein vaccine. In addition,
the STF2R3.2xHA1 format elicits significantly higher levels of
IgG2a and IgG3 compared to the STF2.HA1 format. While IgG1
has been suggested as the most important subclass of neutralizing
antibodies, IgG2a antibodies have been shown to contribute
equally to hemagglutination inhibition in vitro and virus elimination
in BALB/c mice [19]. The higher levels of IgG2a are likely to
correlate to an increased viral clearance due to its Fc receptor (e.g.,
ADCC) and complement activation [20,21]. The higher levels of
IgG3 observed in the STF2R3.2xHA1 groups could be associated
with T cell independent antibody induction in mice.
We have demonstrated that attachment of the HA globular head
at different positions of the flagellin differentially potentiates antibody
responses, resulting in differences in immunogenicity and efficacy
between vaccine candidates (STF2R3.2xHA1.STF2R3.HA1.
STF2.HA1). The immunogenicity profile of these vaccine formats
appearstocorrelatewelltothatofprotectiveefficacyinmice.Wefind
a similar immunogenicity profile in rabbits (unpublished results).
Mice, following intranasal influenza inoculation, develop lethal
pneumonia, and virus replicates to very high titers in the lungs of
infected mice. Although other mechanisms such as IgA and cytolytic
T lymphocytes may have contributed to the excellent efficacy in this
study, serum IgG transudated to the lung is likely to play a major role
in protecting mice against lung infection and death [22]. Using the
well established A/PR/8/34 model, we have been able to fully
protect mice against a lethal virus challenge following passive transfer
of immune sera (unpublished results).
Our data from comparative immunogenicity studies in mice of
currently licensed TIVs and the STF2R3.HA1 candidate indicate
that the STF2R3.HA1 formatcandidate is more immunogenic than
the H1N1 component (A/California/07/2009) of two commercial-
ly available TIVs (Fluvirin and Fluzone, 2010/2011). The
STF2R3.HA1 format was also found to prime mice better than
Fluvirin, demonstrating the superior immunogenicity of VaxIn-
nate’s CA07 vaccine candidate in our preclinical models. This is
presumably due to the immunopotentiating properties of flagellin.
The potential manufacturing advantages of VaxInnate’s vaccine
platform were demonstrated in response to the recent 2009
pandemic influenza when the world was facing challenges in
timely delivery of conventional vaccines. VaxInnate’s pandemic
vaccine platform has significant advantages over the traditional
egg-based flu vaccine manufacturing technology due to its rapid
speed and low cost. The pandemic vaccine candidates tested in
this report proved to be easy to manufacture using standard
biopharmaceutical manufacturing equipment under cGMP con-
ditions, resulting in highly pure vaccines ($95%). At commercial
scale, it is anticipated that over 150 million doses of these vaccines
could be manufactured under cGMP conditions from a single
600 L bioreactor batch, thereby allowing bulk delivery of the
equivalent of 300 million doses of pandemic vaccine within 4–5
months. These vaccine candidates showed an excellent safety and
immunogenicity profile in recent Phase I studies (manuscript in
preparation). Recently, VaxInnate has applied the same flagellin
fusion vaccine platform to several other potential pandemic
influenza strains including H2N3, H5N1 (Indonesia), H7N2,
H7N7, and H9N2 subtypes. Preliminary data from these studies
demonstrated the general suitability of this vaccine platform as a
very promising next generation influenza vaccine technology.
In conclusion, VaxInnate’s pandemic H1N1 vaccine candidates
elicit robust, long-lasting neutralizing antibodies in animal hosts and
are highly effective in protecting mice against lethal viral challenge.
Furthermore, attachment of the HA globular head at different
positions of the flagellin differentially potentiates antibody responses,
resulting in differences in immunogenicity and efficacy between
Figure 2. SDS-PAGE and antigenicity analyses of three purified
recombinant. vaccine candidates. (A) Purified recombinant pro-
teins were separated on an 4–12% SDS PAGE (0.5 mg protein/lane) and
stained with Coomassie Blue. Lane1: STF2.HA1; lane 2: STF2R3.HA1; lane
3, STF2R3.2x HA1; and lane 4, Protein Marker. (B) Reactivity of ferret
post infection serum to various vaccine candidates or reference antigen.
ELISA plates were coated with serially diluted various CA07 proteins or
HA CA04 (Protein Sciences) starting at 320 nmol/l in in PBS, reacted to
ferret anti-CA7 serum, and detected with HRP-conjugated goat anti-
ferret IgG. Mean OD450 of triplicates was read and graphed.
doi:10.1371/journal.pone.0020928.g002
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Materials and Methods
Ethics statement
The mouse immunogenicity studies were conducted in accordance
withtheapprovaloftheInstitutionalAnimalCareandUseCommittee
(IACUC) of Princeton University dated 17 March 2010. Princeton
University has held AAALAC accreditation since October 10, 2002.
The U. S. Government (National Institutes of Health) assurance was
renewed 31 March 2008 for a period of four years (PHS Assurance
No. A3434-01) in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
The mouse efficacy studies were conducted in accordance with
the approval of the IACUC of Utah State University dated 20
Figure 3. Antibody responses in BALB/c mice. Mice were immunized s.c. on days 0 and 21, and bled on day 42. Neutralizing antibody titers and
HA-specific IgG subclasses were measured by HAI test (A, n=10) and ELISA (B, (n=5), respectively, and expressed as GMTs 695%CI. **, p,0.01 in 2-
way ANOVA/Bonferroni test.
doi:10.1371/journal.pone.0020928.g003
Table 1. Purification step, yield, and flagellin bioactivity
a of candidate vaccines.
STF2.HA1 STF2R3.HA1 STF2R3.2xHA1
Expression 75% soluble Inclusion bodies Inclusion bodies
Refolding method Rapid dilution Rapid dilution Rapid dilution
Chromatography AEX, SEC AEX, SEC AEX, SEC
Yield (g purified protein/g cell past) 1.43 1.79 1.67
IL-8 induction (pg/ml) 383639 10026164 553635
aflagellin bioactivity was assessed by measuring secreted IL-8 with a sandwich ELISA (BD Biosciences) as previously described [9]. HEK293 cells in 96-well plates (n=9)
were stimulated with 278 ng/ml of each vaccine candidate for 16–18 hours at 37uC. IL-8 concentrations in medium were calculated from an IL-8 standard curve, and
expressed as means 6 SDs. IL-8 levels of cell control samples were ,=30 pg/ml.
doi:10.1371/journal.pone.0020928.t001
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Laboratory Animal Research Center of Utah State University.
The U. S. Government (National Institutes of Health) approval
was renewed 1 April 2010 (PHS Assurance No. A3801-01) in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (Revision; 2010).
Cloning of recombinant vaccine candidates
Recombinant flagellin-HA globular head genes of the
STF2.HA1 and STF2R3.HA1 candidates were designed and
constructed as previously described [9]. Briefly, codon optimized
synthetic genes of the hemagglutinin (HA) globular head of A/
California/04/2009 fused to the C-terminus, R3 position, or both
positions of the Salmonella typhimurium fljB (flagellin phase 2), STF2
gene were cloned into the pET24a vector to generate the
constructs STF2.HA1 (CA04), STF2R3.HA1 (CA04), and
STF2R3.2x.HA1 (CA04). Subsequently, STF2.HA1 (CA07) and
STF2R3.HA1 (CA07) constructs corresponding to the A/Califor-
nia/07/2009 isolate were generated by mutating a single amino
acid residue in the HA globular head of the corresponding CA04
plasmids.
The plasmid encoding STF2R3.26HA1 (CA07) was made from
a fusion of the DNA from the STF2R3.HA1 (CA07) and the
STF2.HA1 (CA07) plasmids. For this, both plasmids were digested
separately with NdeI and MfeI enzymes. Specific fragments of the
STF2R3.HA1 (CA07) (as insert) and STF2.HA1 (CA07) (as vector)
were gel purified and ligated to form a complete DNA sequence
encoding STF2R3.2xHA1 (CA07). The common restriction site is
in the N terminal section of STF2. The DNA sequence of all
plasmids was confirmed by Genewiz Inc. (South Plainfield, NJ).
For protein expression, sequence confirmed plasmids were
transformed into BL21 (DE3) strain of E. coli cells (Novagen,
San Diego, CA). Cell lysates were evaluated by 4–12% NuPAGE
(Invitrogen, Carlsbad, CA), individual protein bands correspond-
ing to the expected molecular weights of the vaccine candidates
were easily visualized by Coomassie Blue staining and Western
blot analyses.
Protein expression and purification
All three proteins (STF2.HA1, STF2R3.HA1, and
STF2R3.2xHA1) were expressed and purified using similar
process steps modified from those previously described [9]. Briefly,
target protein was expressed in batch bioreactor cultures and
isolated to high purity using standard biopharmaceutical process-
es. Bulk protein was formulated by dilution into formulation buffer
for subsequent testing.
The fermentation processes were identical for the three proteins.
Banked cells were cultured in shake flasks using a modified LB
media and inoculated into a bioreactor containing similar media.
After a period of growth controlled for pH, temperature and
dissolved oxygen, cells were induced by IPTG and harvested.
Target protein was purified using a standard protocol with
minor variations between the proteins. After harvest, protein was
released from the cells by homogenization and purified by
clarification, refolding/capture chromatography, polishing chro-
matography, and bulk formulation. STF2.HA1 is mostly expressed
as a soluble protein and was clarified primarily by precipitation
(Table 1). STF2R3.HA1 and STF2R3.2xHA1 are expressed as
Figure 4. HAI titers of mice immunized with STF2R3.HA1, and/
or TIV. Mice (n=10) were primed (P) and boosted (B) with F147,
STF2R3.HA1 (R3), Fluvirin (FluV), or Fluzone (FluZ) at the indicated doses
on days 0 and 21, and bled on day 42 (A). Separate groups of mice
(n=5) were primed with 3 mg of STF2R3.HA1 or F147, and boosted with
3 mg Fluvirin (B). Neutralizing antibody titers were measured by HAI
test, and expressed as GMTs +95%CI (A) or GMTs (B). Doses of Fluvirin
and Fluzone are given according to the contents of H1N1 HA.
***, p,0.001 in 2-way ANOVA/Bonferroni test (A) or 1-way ANOVA/
Tukey test (B).
doi:10.1371/journal.pone.0020928.g004
Figure 5. Longevity of neutralizing antibody response. Mice
(n=5) were immunized s.c. with the indicated candidates (1 mg/mouse),
and bled monthly for 10 months. Serum neutralizing antibody titers
were measured by HAI assay and expressed as GMTs +95%CI.
Immunization time points (days 0, 21 and 266) are given in arrows.
doi:10.1371/journal.pone.0020928.g005
Flagellin-HA Fusion Vaccines of Pandemic Influenza
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(Table 1). After clarification, proteins were resolubilized in urea
buffer, refolded by rapid dilution, and captured by binding AEX
chromatography (Super Q, Tosoh Biosciences LLC., King of
Prussia, PA). Post-capture polishing purification was performed by
size exclusion chromatography (Superdex 2000, GE Healthcare
BioSciences, Piscataway, NJ) using F147 formulation buffer
(10 mM Tris, 10 mM Histidine, 150 mM NaCl, 5% Trehalose,
0.02%, polysorbate 80, 0.1 mM EDTA, 0.5% Ethanol, pH 7.0) as
mobile phase. Resulting protein preparations were at least 90%
pure by reverse phase chromatography, contained #2% aggre-
gates, and contained low concentrations of endotoxin, host cell
proteins, and nucleic acids.
Viruses and cells
Influenza A/California/07/2009 virus was obtained from the
US Center for Disease Control and Prevention (Atlanta, GA),
amplified in 10-day old SPF research eggs (Charles River
Laboratories Inc., Storrs, CT), and titrated by hemagglutination
test using Turkey red blood cells (Lampire Biologicals Lab,
Pipersville, PA). Mouse-adapted influenza A/California/04/2009
received from Dr. Elena Govorkova (Department of Infectious
Diseases, St. Jude Children’s Research Hospital, Memphis, TN)
was propagated and titrated in MDCK cells at Utah State
University. The virus was adapted to replicate in the lungs of
BALB/c mice by 9 sequential passages through mouse lungs [23].
Virus was plaque purified in MDCK cells in minimal essential
medium (MEM/EBSS, HyClone Laboratories, Inc., Logan Utah).
A working virus stock was prepared by growth in embryonated
hens’ eggs and then MDCK cells.
ELISA for measurement of antigenicity
ELISA plates were coated with the following antigens:
recombinant STF2.HA1, STF2R3.HA1, STF2R3.2xHA1, and
baculovirus expressed HA0 CA04 (Protein Sciences, Meriden,
CT). Triplicate wells were coated with serial dilutions starting at
320 nM and incubated overnight at 4uC. Plates were blocked with
300 ml/well of SuperBlock T20 buffer (Thermo Fisher Scientific,
Rockford, IL) for 2 hours at room temperature. Plates were
washed three times with wash buffer (PBS supplemented with
0.05% Tween-20), ferret post A/California/07/2009 infection
serum (1:400 dilution, CDC) was added, and plates were
incubated for 1.5 hr at room temperature. Plates were washed
three times with wash buffer, HRP-conjugated goat anti-ferret IgG
Figure 6. Effects of immunization on mean weight changes and day 4 lung virus titers of infected mice. Mice (n=15) were immunized
s.c. on days 0 and 21, and challenged I.N. with A/California/04/2009 on day 42 (experiment 2 in Table 1). Infected mice were monitored daily for
weight change for 21 days. Four days post infection, lungs were collected from selected groups and subjected to TCID50 test. (A) Mean weight
change (n=10): a very significant difference was found in the mean weight change for all the vaccinated groups compared to the placebo (p,0.001)
in 1-way ANOVA/Tukey test. (B) Lung virus titers (n=5, means 6 SDs) **, p,0.01, ***, p,0.001 in 2-way ANOVA/Bonferroni test.
doi:10.1371/journal.pone.0020928.g006
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were incubated at room temperature for 45 min. After adding
TMB-ELISA substrate and then stop buffer, the mean OD450 of
triplicate wells was determined and graphed.
ELISA for measurement of IgG subclasses in serum
ELISA plates were coated with 0.2 mg/well HA0 CA04
(Proteins Sciences, Meriden, CT) or serially diluted mouse
polyclonal IgG standard. After washing, the plates were blocked
with Assay Diluent (BD Biosciences, San Diego, CA) for one hour.
Serially diluted mouse immune serum samples were added; and
plates were incubated for 1 hour at room temperature. After
washing three times with wash buffer, HRP-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch Labs, West Grove, PA) was
added and incubated at room temperature for 45 min. After
adding TMB-ELISA substrate and then stop buffer, the mean
OD450 of duplicates was determined and graphed. Quantification
(specific IgG in mg/ml) is performed using a standard curve of
polyclonal IgG coated on the same plate, fitted with a 4-parameter
logistic equation (Softmax 5.2, Molecular Devices, CA). Data are
reported as results of individual mice.
Hemagglutination inhibition (HAI) test
The HAI test was performed as previously described [14]. Post-
boost serum samples were treated with receptor destroying
enzyme (RDE) II overnight, heat-inactivated (56uC 45 min),
diluted in 96-well V-bottom microtiter plates, and incubated with
4 HA units (HAU) of influenza A/California/07/2009 virus in
25 ml for 30 minutes at room temperature. Turkey red blood cells
(TRBC, 0.5%) (Lampire Biological Laboratories, Pipersville, PA)
were added (50 ml/well), mixed briefly, and incubated for 30–
60 min at room temperature. The HAI titers of serum samples are
reported as the reciprocal of the highest dilution at which
hemagglutination was completely inhibited. Sheep anti-A/Cali-
fornia/07/2009 serum (CBER, FDA) or ferret post infection anti-
A/California/07/2009 serum (CDC) was used as reference serum
to monitor the variability among different tests.
TCID50 test
Mouse lungs were homogenized in 1 ml of MEM/EBSS
medium and assayed for infectious virus in MDCK cells, as
described previously [24]. Samples were serially diluted in 10-fold
increments in 96-well plates of MDCK cells. Four wells were used
per virus dilution. Cytopathic effects induced by the virus were
determined at 3 and 6 days, with virus titers calculated by the
method of Reed and Muench (1938) [25]. Fifty percent cell culture
infectious doses (TCID50) were converted to TCID50 per gram of
lung tissue prior to statistical analysis. The limit of detection for the
TCID50 assay was 0.75 log10 unit.
Immunogenicity studies
Immunogenicity studies were conducted at Princeton University
following an IACUC-approved protocol. Groups of ten female
BALB/c mice (6–8 week old, Charles River Lab, Wilmington,
MA) were immunized subcutaneously (s.c.) on days 0 and 21 with
0.2–5 mg of STF2.HA1, STF2R3.HA1, and STF2R3.2xHA1
candidate vaccines, a commercial TIV Fluvirin (Novatis) or
Fluzone (Sanofi-Aventis). Blood was collected via retro-orbital
puncture on day 35 or 42. And serum samples were prepared
following centrifugation, and stored at 220uC until use.
Mouse efficacy studies
Mouse efficacy studies were conducted at Utah State University.
Groups of 15 female BALB/c mice (6 week old) were immunized
s.c. on days 0 and 21, and bled on day 35 to prepare immune sera.
Animals were anesthetized with a ketamine (100 mg/kg)/xylazine
Table 2. HAI titers and survival rates of immunized mice.
Vaccines Dose (mg) Experiment 1 Experiment 2
GMT (SP) Survival (%) GMT (SP) Survival (%)
STF2.HA1 3 116 (93) 100*** 91 (64) 100***
0.3 17 (33) 100*** 19
c (44) 100***
0.03 5 (0) 20 6
d (0) 90**
STF2R3.HA1 3 139 (93) 100*** 300 (100) 100***
0.3 30
a,b (60) 100*** 53 (67) 100***
0.03 6 (0) 60* 10 (7) 100***
STF2R3.2xHA1 3 211 (93) 100*** 234 (100) 100***
0.3 88 (93) 100*** 153 (87) 100***
0.03 10 (20) 90***
,e 22 (33) 100***
F147 N/A 5 (0) 0 6 (0) 10
Mice were immunized s.c. on days 0 and 21, bled on day 35, and challenged I.N. with 500 TCID50 of mouse adapted A/California/04/2009 on day 42. Infected mice were
monitored daily (n=10) for mortality for 21 days. SP: seroprotective titer, mice% with $40 HAI titers.
Two-way ANOVA/Boferroni tests for HAI data (n=15):
a, p,0.01 (**) vs STF2.HA1;
b, p,0.001 (***) vs STF2R3.2xHA1;
c, p,0.001 (***) vs STF2R3.2xHA1;
d, p,0.05 vs STF2R3.2xHA1.
Fisher’s exact test for survival data (n=10):
*, p,0.05;
**, p,0.01;
***, p,0.001;
e, p,0.05 (*) vs STF2.HA1 at the same dose (0.03 mg/mouse).
doi:10.1371/journal.pone.0020928.t002
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adapted A/California/04/2009 (500 TCID50 in a 90-ml volume
per mouse) on day 42. Animals were monitored daily for morbidity
and mortality for 21 days. Four days after the viral infection, five
mice from selected groups were euthanized; lung samples were
collected to measure the virus titers by TCID50 assay.
Statistical analyses
The titers of neutralizing antibodies and virus titers were log10-
transformed, and subjected to 1-way ANOVA or 2-way ANOVA
analysis with Tukey or Bonferroni post tests using GraphPad
Prism 5.00 (GraphPad Software, San Diego, CA). Survival curves
between different groups were compared with Fisher’s exact test.
The mean body weights were analyzed by ANOVA followed by
Tukey’s multiple comparison test using Prism 5.0.
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